Brief: TCR² Therapeutics Reports Positive Interim Results from Ongoing Trial of Gavo-cel

TCR2 Therapeutics

17/09/2021 12:33

Sept 17 (Reuters) - TCR2 Therapeutics Inc  TCRR.O :
    * TCR² THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM
ONGOING PHASE 1/2 TRIAL OF GAVO-CEL FOR TREATMENT REFRACTORY
MESOTHELIN-EXPRESSING SOLID TUMORS
    * TCR2 THERAPEUTICS INC - CLINICAL ACTIVITY OBSERVED IN ALL
THREE
MESOTHELIN-EXPRESSING TUMOR TYPES TREATED
    * TCR2 THERAPEUTICS INC - GAVO-CEL DISEASE CONTROL RATE 81%
WITH
TUMOR REGRESSION IN 15 OF 16 EVALUABLE PATIENTS
    * TCR2 THERAPEUTICS - OVERALL RESPONSE RATE 31% IN PATIENTS
INFUSED WITH GAVO-CEL FOLLOWING LYMPHODEPLETION
    * TCR2 THERAPEUTICS INC - MEANINGFUL SURVIVAL BENEFIT AT
11.2
MONTHS FOR PATIENTS WITH REFRACTORY MESOTHELIOMA
    * TCR2 THERAPEUTICS - RECOMMENDED PHASE 2 DOSE BEING REFINED
AFTER
IDENTIFICATION OF MAXIMUM TOLERATED DOSE
    * TCR2 THERAPEUTICS INC - GAVO-CEL WAS GENERALLY WELL
TOLERATED
WITH A MANAGEABLE ADVERSE EVENT PROFILE

Source text for Eikon:  ID:nGNXjbJ3Z 
Further company coverage:  TCRR.O 

 ((Reuters.Briefs@thomsonreuters.com;))